TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and In Silico Search for Small Molecule Binders

There is now compelling evidence that TNF receptor type II (TNFR2) is predominantly expressed on CD4(+)Foxp3(+) regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and plays a major role in the expansion and function of Tregs and MDSCs. Consequently, targeting of TNFR2 by either...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaikh, Faraz, He, Jiang, Bhadra, Pratiti, Chen, Xin, Siu, Shirley W. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015900/
https://www.ncbi.nlm.nih.gov/pubmed/29967617
http://dx.doi.org/10.3389/fimmu.2018.01382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015900/
https://www.ncbi.nlm.nih.gov/pubmed/29967617
http://dx.doi.org/10.3389/fimmu.2018.01382

Ejemplares similares